Department of Cardiovascular and Thoracic Surgery, University of Texas Southwestern Medical Center, Dallas, Texas, 75390-9130.
Office of Research, Technology Translation Laboratory, University of Texas at Dallas, Richardson, Texas, 75080-3021.
J Biomed Mater Res B Appl Biomater. 2017 Oct;105(7):2153-2161. doi: 10.1002/jbm.b.33754. Epub 2016 Jul 18.
Current interventional technology for pediatric airway obstruction consists of cardiovascular stents and silicon tubes. These devices are composed of permanent materials that have limitations in biocompatibility and mechanical properties that make them controversial for used in pediatrics. Bioresorbable stents offer a temporary intervention that dissolves in the body over time and can serve as a platform for local drug delivery. Here we investigate a novel approach to use an antibiotic, ciprofloxacin, as a polymerization initiator to synthesize poly(ciprofloxacin fumaric acid) (PCFA) and then a second polymer using gadodiamide as an initiator to synthesize poly(gadodiamide ciprofloxacin fumaric acid) (PGCFA). Polymer structure, degradation, thermal properties, and rheological behavior were analyzed. Ciprofloxacin released was determined and polymer degradation extracts were used in bacterial sensitivity assessments with four common airway pathogens. PCFA and PGCFA polymers and drug release properties were compared to our previously published polymer poly(fumaric acid) (PFA). These novel polymers enable new possibilities as coatings for bioresorbable biomedical applications that require antibiotic resistance and imaging capabilities. © 2016 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 105B: 2153-2161, 2017.
目前用于小儿气道阻塞的介入技术包括心血管支架和硅管。这些设备由永久性材料组成,在生物相容性和机械性能方面存在局限性,因此在儿科应用中存在争议。可吸收支架提供了一种临时介入,随着时间的推移在体内溶解,并可作为局部药物输送的平台。在这里,我们研究了一种新方法,即用抗生素环丙沙星作为聚合引发剂合成聚(环丙沙星富马酸)(PCFA),然后用钆喷酸二胺作为引发剂合成聚(钆喷酸环丙沙星富马酸)(PGCFA)。分析了聚合物的结构、降解、热性能和流变性能。测定了释放的环丙沙星,并对四种常见气道病原体进行了细菌敏感性评估,使用聚合物降解提取物。将 PCFA 和 PGCFA 聚合物及其药物释放性能与我们之前发表的聚合物聚(富马酸)(PFA)进行了比较。这些新型聚合物为需要抗生素耐药性和成像能力的可吸收生物医学应用的涂层提供了新的可能性。©2016 年威利父子公司。J 生物医学材料研究部分 B: 应用生物材料,105B:2153-2161,2017.